Bourgeon Capital Management LLC Has $253,000 Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Bourgeon Capital Management LLC lessened its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 16.7% in the fourth quarter, HoldingsChannel reports. The firm owned 118,700 shares of the company’s stock after selling 23,880 shares during the period. Bourgeon Capital Management LLC’s holdings in Allogene Therapeutics were worth $253,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Federated Hermes Inc. acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at approximately $29,000. Private Advisor Group LLC bought a new stake in Allogene Therapeutics in the third quarter valued at approximately $34,000. Algert Global LLC acquired a new stake in Allogene Therapeutics in the second quarter worth $35,000. MML Investors Services LLC bought a new position in shares of Allogene Therapeutics during the third quarter worth $56,000. Finally, AQR Capital Management LLC acquired a new position in shares of Allogene Therapeutics in the 2nd quarter valued at $64,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Trading Up 1.1 %

Shares of ALLO opened at $1.84 on Wednesday. Allogene Therapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $5.78. The firm has a fifty day simple moving average of $2.15 and a 200 day simple moving average of $2.52. The stock has a market capitalization of $385.80 million, a price-to-earnings ratio of -1.18 and a beta of 0.86.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Piper Sandler cut their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).